POINT Biopharma

POINT Biopharma is a radiopharmaceutical company dedicated to developing targeted radioligand therapies for cancer treatment. As a wholly owned subsidiary of Eli Lilly and Company, POINT focuses on clinical and preclinical-stage therapies that aim to precisely target specific cancer types. Their lead programs include PNT2002, which targets prostate-specific membrane antigen (PSMA) for metastatic castration-resistant prostate cancer, and PNT2003, aimed at somatostatin receptors for gastroenteropancreatic neuroendocrine tumors. The integration into Eli Lilly's oncology portfolio enhances their capabilities in next-generation radioligand therapies. POINT Biopharma's work combines radioactive isotopes with targeting molecules to deliver radiation directly to cancer cells, minimizing harm to healthy tissue. Their efforts are geared towards expanding treatment options for challenging cancers, benefiting oncology patients and healthcare providers seeking innovative therapies.